Bioharvest Sciences, Inc. ((BHST)) has held its Q3 earnings call. Read on for the main highlights of the call.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Bioharvest Sciences, Inc. recently held its earnings call, revealing a balanced sentiment marked by impressive revenue growth and successful capital raising, yet tempered by ongoing net losses and rising operating expenses. The company showcased significant achievements, particularly in the CDMO segment, while also acknowledging the challenges it faces.
Significant Revenue Growth
Bioharvest Sciences reported a remarkable 39% year-over-year increase in total revenues, reaching $9.1 million. This growth was primarily driven by the sustained momentum of its core VINIA capsules and the expanding success of the VINIA Inside product portfolio.
CDMO Business Expansion
The company’s CDMO segment experienced a staggering 722% growth, generating $0.7 million in revenue. A notable highlight was the new partnership with Saffron Tech to develop saffron-derived compounds, with BioHarvest retaining a 25% ownership stake.
Successful Capital Raise
Bioharvest successfully completed a $19.9 million institutional equity financing, bringing total gross proceeds from recent efforts to $30.8 million. This capital raise has significantly strengthened the company’s balance sheet.
Gross Profit Margin Improvement
Gross profit increased by 50% to $5.6 million, with gross margins rising to 61%. This improvement was attributed to increased manufacturing scale and improved yields.
VINIA BloodFlow Hydration Launch
The company launched an early access rollout of VINIA BloodFlow Hydration, targeting the $17 billion U.S. electrolyte hydration market, marking a strategic expansion into new product categories.
Continued Net Losses
Despite the positive revenue growth, Bioharvest reported net losses of $2.5 million for Q3 2025, a slight improvement from the $2.7 million loss in the same quarter of the previous year.
Increased Operating Expenses
Operating expenses rose to $6.5 million from $5.8 million, driven by increased marketing spend and development costs for the Health Pros affiliate program.
Forward-Looking Guidance
Looking ahead, Bioharvest Sciences anticipates fourth-quarter revenues between $9 million and $9.5 million, with adjusted EBITDA nearing breakeven. The company aims to expand its direct-to-consumer and CDMO operations, supported by a strengthened balance sheet and a growing U.S. VINIA active user base.
In summary, Bioharvest Sciences’ earnings call reflected a balanced sentiment with notable achievements in revenue growth and capital raising, offset by challenges of net losses and rising expenses. The company remains optimistic about its future prospects, with strategic expansions and financial fortification paving the way for potential profitability.